Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $125K invested in Lixte Biotechnology Warrants in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.89% more ownership
Funds ownership: 0.32% → 1.21% (+0.89%)
25% less funds holding
Funds holding: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $173K → $125K (-$48K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$17K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$12.3K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$8.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $107K | -$12.3K | -17,285 | -11% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $11K | -$8.73K | -12,246 | -46% |
|
|
3
UBS Group
Zurich,
Switzerland
| $7K | +$1.32K | +1,855 | +26% |
|
|
4
Morgan Stanley
New York
| – | -$17K | -21,053 | Closed |
|
LIXTW Hedge Fund Activity: Q2 2021 in Review
3 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q2 2021, worth a combined $125K — down 28% from $173K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LIXTW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $1.32K. The largest seller was Morgan Stanley, exiting entirely with an estimated $17K sold.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q2 2021, down from 4 in Q1 2021.
- Funds reported $125K of Lixte Biotechnology Warrants stock for Q2 2021, down 28% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q2 2021 and 1 closed out, a net change of -1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q2 2021 was UBS Group, an estimated $1.32K added.
- The largest Lixte Biotechnology Warrants seller in Q2 2021 was Morgan Stanley, an estimated $17K sold.
Based on aggregated 13F filings for Q2 2021.